Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8176 to 8190 of 8199 results

  1. Consultation on updated guideline to assess and prevent falls in older people

    We're seeking views from healthcare professionals and the public on draft recommendations covering assessments and interventions to reduce the risk of falls in older people.

  2. First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE

    For the first time, we have recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce the risk of the disease coming back.

  3. Consultation on NHS England proposals for a phased launch of obesity injection

    Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins.

  4. NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer

    Today (1 October 2024) NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer.

  5. NICE Board says new method allowing greater weight to be given to severe diseases is working

    At today's meeting (25th September 2024) our board has concluded that the new severity modifier is working as intended.

  6. Adults with Von Hippel-Lindau disease to benefit from new treatment

    NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people.

  7. Emergency kits for people with adrenal insufficiency recommended to avoid hospital admission

    People with adrenal insufficiency should be given an emergency medical kit with potentially life-saving steroid injections, according to our new clinical guideline.

  8. Thousands could benefit from new option for treating symptoms of uterine fibroids

    As many as 30,000 adults could benefit from a new treatment for moderate to severe symptoms of uterine fibroids after we published final guidance today (14 August 2024) recommending linzagolix.

  9. World's first gene editing therapy for blood disorder to be available to hundreds of patients in England

    Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.

  10. 14,000 women at risk of fractures after the menopause to benefit from bone disease drug

    Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.

  11. NICE disappointed companies unwilling to offer fair price to make Enhertu available for advanced breast cancer

    Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.

  12. New clot-busting drug recommended by NICE set to save NHS £millions

    Giving a new clot-busting drug to people who have had a stroke could help save the NHS millions of pounds.

  13. More than 40,000 people could benefit after NICE recommends new 'take at home' pill for advanced prostate cancer

    Thousands of people could benefit from a new oral hormone therapy for advanced hormone sensitive prostate cancer.

  14. NICE recommends digital technology to help diagnose ADHD in children and young people

    A digital technology that will help healthcare professionals provide a quicker diagnosis to people with attention deficit hyperactivity disorder (ADHD) can be used by the NHS, NICE has said in draft guidance.

  15. New study shows NICE Advice support can reduce appraisal timelines by 3 months

    Companies who receive scientific advice from our NICE Advice service may experience a faster path to guidance publication, a study has found.